Department of Cardiac Surgery, Beijing Anzhen Hospital, Capital Medical University, Beijing Institute of Heart, Lung and Blood Vessel Diseases, Beijing, China.
Department of Aortic Surgery, The State Key Laboratory of Cardiovascular Disease, Fuwai Hospital, National Center for Cardiovascular Disease, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.
Eur J Cardiothorac Surg. 2019 Jun 1;55(6):1054-1060. doi: 10.1093/ejcts/ezy440.
The aim of this study is to evaluate the safety and efficacy of thoraco-abdominal aortic aneurysm repair with normothermic iliac perfusion.
One hundred and ninety patients who underwent aortic replacement for the Crawford type II thoraco-abdominal aortic aneurysm between January 2005 and June 2017 were assigned to 2 groups: normothermic iliac perfusion (group A, n = 75) and deep hypothermic circulatory arrest (group B, n = 115). We selected 58 pairs of patients for propensity score matching. We analysed early operative death, a composite of complications and mid-term survival.
After propensity score matching, no early operative death occurred in group A (0.0%), and group B had 4 cases of early operative death (6.9%), with a statistically significant difference (P = 0.047). The composite of complications was reported in 11 patients in group A (21.0%) and in 21 patients in group B (36.2%) (P = 0.038). Age >50 years [odds ratio (OR) 6.50, 95% confidence interval (CI) 2.32-16.36; P = 0.020], deep hypothermia (OR 12.13, 95% CI 1.64-23.13; P = 0.003) and chronic renal insufficiency (OR 8.21, 95% CI 2.34-43.33; P < 0.001) were independent risk factors for early operative death. The 3-year, 5-year and 7-year survival rates were 98.3%, 98.3% and 86.9% in group A and 86.9%, 86.9% and 86.9% in group B, respectively (P = 0.471). The 7-year cumulative incidence function rates for reintervention were 0.026% in group A and 0.048% in group B (P = 0.625).
Normothermic iliac perfusion provides a viable alternative for thoraco-abdominal aortic aneurysm repair, which reduced early operative death and composited complications.
本研究旨在评估常温髂动脉灌注在胸腹主动脉瘤修复中的安全性和疗效。
2005 年 1 月至 2017 年 6 月,对 190 例 Crawford Ⅱ型胸腹主动脉瘤患者进行主动脉置换,分为两组:常温髂动脉灌注组(A 组,n=75)和深低温停循环组(B 组,n=115)。我们选择了 58 对患者进行倾向评分匹配。我们分析了早期手术死亡率、并发症复合终点和中期生存率。
经倾向评分匹配后,A 组无早期手术死亡(0.0%),B 组有 4 例早期手术死亡(6.9%),差异有统计学意义(P=0.047)。A 组有 11 例(21.0%)和 B 组有 21 例(36.2%)患者报告有复合并发症(P=0.038)。年龄>50 岁[比值比(OR)6.50,95%置信区间(CI)2.32-16.36;P=0.020]、深低温(OR 12.13,95%CI 1.64-23.13;P=0.003)和慢性肾功能不全(OR 8.21,95%CI 2.34-43.33;P<0.001)是早期手术死亡的独立危险因素。A 组 3 年、5 年和 7 年生存率分别为 98.3%、98.3%和 86.9%,B 组分别为 86.9%、86.9%和 86.9%(P=0.471)。A 组 7 年再干预累积发生率为 0.026%,B 组为 0.048%(P=0.625)。
常温髂动脉灌注为胸腹主动脉瘤修复提供了一种可行的替代方法,可降低早期手术死亡率和复合并发症发生率。